Last Updated: August 15, 2026

Claims for Patent: 12,329,750

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 12,329,750

Title:	Treatment of migraine
Abstract:	The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.
Inventor(s):	Joel M. Trugman, Ramesh BOINPALLY, Abhijeet Jakate, Michelle Finnegan
Assignee:	Allergan Pharmaceuticals International Ltd
Application Number:	US18/924,415
Patent Claims:	1. A method for the acute treatment of migraine with or without aura in a patient undergoing concurrent treatment with a BCRP and/or P-gp only inhibitor, the method comprising orally administering an initial dose of 50 mg ubrogepant to the patient, wherein the patient's migraine is safely and effectively treated. 2. The method of claim 1, comprising orally administering a second dose of 50 mg ubrogepant to the patient at least 2 hours after the administration of the initial dose of 50 mg ubrogepant. 3. The method of claim 2, wherein the second dose of 50 mg ubrogepant is administered to the patient between 2 and 24 hours after the administration of the initial dose of 50 mg ubrogepant. 4. The method of claim 1, wherein the patient achieves freedom from at least one migraine symptom within 2 hours after the administration of the initial dose of 50 mg ubrogepant.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.